DL 06002Alternative Names: DL06002
Latest Information Update: 26 Jul 2007
At a glance
- Originator DanioLabs
- Class Antiparkinsonians
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hyperhidrosis
Most Recent Events
- 03 Jul 2006 Phase-I clinical trials in Hyperhidrosis in United Kingdom (unspecified route)
- 03 Jul 2006 DanioLabs has initiated enrolment in a phase I trial for hyperhidrosis in the UK